Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection

Background: Antibiotics targeted against Clostridioides difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biolo...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Barbara, Sims, Mathew, Kraft, Colleen, Wang, Elaine, Brady, Kelly, Ford, Christopher, Edward, O’Brien, Lombardo, Mary-Jane, Wortman, Jennifer, Litcofsky, Kevin, Mahoney, Jennifer, McChalicher, Christopher, Winkler, Jonathan, Garant, Sarah, Aunins, John, Henn, Matthew, von Moltke, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
C. difficile
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551515/
http://dx.doi.org/10.1017/ash.2021.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551515/
http://dx.doi.org/10.1017/ash.2021.10

Ejemplares similares